Literature DB >> 853526

Regression of established intradermal tumors and lymph node metastases in guinea pigs after systemic transfer of immune lymphoid cells.

H G Smith, R P Harmel, M G Hanna, B S Zwilling, B Zbar, H J Rapp.   

Abstract

Strain-2 male guinea pigs with established intradermal (id) tumors and microscopic regional lymph node metastases were treated by systemic transfer of syngeneic peritoneal exudate (PE) cells from tumor-immune guinea pigs. This treatment produced complete regressions of established id tumor nodules (10-11 mm in diameter) and prevented the growth of lymph node metastases in 32 (80%) of the 40 treated animals. All untreated animals died with progressive id and lymphatic tumor growth. Lymph node tumor metastases that remained after id tumor excision were also suppressed by immune cell transfer. PE cells from guinea pigs immune to an antigenically distinct tumor line (line-1), BCG, or PE cells from nonimmune guinea pigs failed to produce tumor regression or prolongation of survival time. PE cells from allogeneic guinea pigs and from sheep immune to line-10 failed to transfer tumor immunity to strain-2 guinea pigs. The effectiveness of therapy was reduced by increasing the tumor burden or decreasing the number of transferred lymphoid cells. This study demonstrated that systemic transfer of cells from syngeneic immune donors could effectively eliminate tumors as well as early metastases.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 853526     DOI: 10.1093/jnci/58.5.1315

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  12 in total

Review 1.  State of melanoma: an historic overview of a field in transition.

Authors:  Vikram C Gorantla; John M Kirkwood
Journal:  Hematol Oncol Clin North Am       Date:  2014-06       Impact factor: 3.722

Review 2.  The adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S E Ettinghausen; S A Rosenberg
Journal:  Springer Semin Immunopathol       Date:  1986

Review 3.  Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.

Authors:  E A Fagan; A L Eddleston
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

Review 4.  Modulation of antitumor immunity--immunobiologic approaches.

Authors:  R J North; E S Dye; C D Mills; J P Chandler
Journal:  Springer Semin Immunopathol       Date:  1982

5.  Adoptive chemoimmunotherapy of a syngeneic murine lymphoma with long-term lymphoid cell lines expanded in T cell growth factor.

Authors:  T J Eberlein; M Rosenstein; P Spiess; R Wesley; S A Rosenberg
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Lysis of colonic epithelial cells by allogeneic mononuclear and lymphokine activated killer cells derived from peripheral blood and intestinal mucosa: evidence against a pathogenic role in inflammatory bowel disease.

Authors:  P R Gibson; E van de Pol; W Pullman; W F Doe
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

7.  Adoptive immunotherapy mediated by anti-TCR/IL-2-activated tumour-draining lymph node cells.

Authors:  S Mitsuma; H Yoshizawa; K Ito; H Moriyama; M Wakabayashi; T Chou; M Arakawa; S Shu
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

8.  Failure of specific adoptive immunotherapy owing to survival and outgrowth of variant cells.

Authors:  D L Hines
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

9.  Regression by active specific immunotherapy of established dermal tumor transplants and lymph node metastases in guinea pigs.

Authors:  E Yarkoni; H J Rapp
Journal:  Infect Immun       Date:  1981-01       Impact factor: 3.441

10.  Anti-tumour activity of Lactobacillus casei on Lewis lung carcinoma and line-10 hepatoma in syngeneic mice and guinea pigs.

Authors:  T Matsuzaki; T Yokokura; I Azuma
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.